Cancers · 2022 · 14 citations · 37 references
MedicineMolecular MedicineOncologyMolecular DiagnosticsMolecular OncologyPrecision MedicineBiomarker ValidationCancer BiomarkersCirculating Tumor Dna AnalysisColorectal CancerLiquid BiopsyTumor MarkersCirculating Cell-free Dna AnalysisCirculating Tumor Dna DetectionCirculating Tumor Dna TestingLiquid Biopsy Biomarker ValidationLiquid Biopsy PrognosisPredictive Marker AssessmentResidual Disease ThresholdsTumor Burden Measurement
Circulating tumor DNA (ctDNA) is a promising liquid biopsy (LB) marker to support clinical decisions in precision medicine. For implementation into routine clinical practice, clinicians need precise ctDNA level cutoffs for reporting residual disease and monitoring tumor burden changes during therapy. We clinically validated the limit of blank (LOB) and the limit of quantification (LOQ) of assays for the clinically most relevant somatic variants BRAF p.V600E and KRAS p.G12/p.G13 in colorectal cancer (CRC) in a study cohort encompassing a total of 212 plasma samples. We prove that residual disease detection using the LOB as a clinically verified cutoff for ctDNA positivity is in concordance with clinical evidence of metastasis or recurrence. We further show that tumor burden changes during chemotherapy and the course of disease are correctly predicted using the LOQ as a cutoff for quantitative ctDNA changes. The high potential of LB using ctDNA for accurately predicting the course of disease was proven by direct comparison to the routinely used carcinoembryonic antigen (CEA) as well as the circulating free DNA (cfDNA) concentration. Our results show that LB using validated ctDNA assays outperforms CEA and cfDNA for residual disease detection and the prediction of tumor burden changes.
37
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Eric Van Cutsem, Andrés Cervantes, René Adam et al. · Annals of Oncology · 2016 · 3.4K citations · Full text
Circulating mutant DNA to assess tumor dynamics
Frank Diehl, Kerstin Schmidt, Michael A. Choti et al. · Nature Medicine · 2008 · 2.7K citations · Full text
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Fátima Cardoso, A. Costa, Elżbieta Senkus et al. · Annals of Oncology · 2016 · 2.1K citations · Full text
Medicine, Oncology, Breast Oncology +11